1,10-Dibromodecane | CAS:4101-68-2

We serve 1,10-Dibromodecane CAS:4101-68-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
1,10-Dibromodecane

Chemical Name:1,10-Dibromodecane
CAS.NO:4101-68-2
Synonyms:1,10-Dibromodecane
1,10-DibroModecane
Decene,1,10-dibromo
Decane, 1,10-dibromo-
Molecular Formula:C10H20Br2
Molecular Weight:300.07400
 
Physical and Chemical Properties:
Density:1.335
Melting point:25-27ºC
Boiling point:160ºC
Flash point:26ºC
Index of Refraction:1.4912
 
Specification:
Appearance:White solid or colorless liquid
Assay:≥99.0%
Moisture:≤0.3%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Organic synthesis intermediate



Contact us for information like 1,10-Dibromodecane chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Decane, 1,10-dibromo- physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1,10-DibroModecane Use and application,1,10-Dibromodecane technical grade,usp/ep/jp grade.


Related News: The injection has previously proven to be as effective as standard daily pills with three active ingredients when administered monthly and also once every two months.N,N'-(4,6-Dichloropyrimidine-2,5-diyl)diformamide manufacturer The Department of Health and Human Services asked the Defense Department to provide several facilities capable of housing at least 250 people in individual rooms through to February 29, the Pentagon said.2-Chloro-4-fluorobenzoic acid supplier It is understood that at present, the industry competition for global characteristic APIs has shown a development trend of vertical integration, and the number of mergers and acquisitions between pharmaceutical manufacturers and API manufacturers is increasing.2-nitro-p-toluidine vendor In recent years, the government has heavily promoted TCM, as part of efforts by Xi to bolster the country’s health sector and fill the gaps in national insurance schemes.At Day 35 following administration, a bone marrow assessment showed that FT819 persisted and continued to demonstrate tumor clearance, whereas primary CAR T cells, while persisting, were not able to control tumor growth.